CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377)

被引：0
|
作者：
Jordan, Stanley [1 ]
Ammerman, Noriko [1 ]
Toyoda, Mieko [2 ]
Ge, Shili [2 ]
Huang, Edmund [1 ]
Peng, Alice [1 ]
Sethi, Supreet [1 ]
Najjar, Reiad [1 ]
Ortiz, Edwin [2 ]
Chu, Maggie [2 ]
De Guzman, Abner [2 ]
Kim, Irene [1 ]
Lim, Kathlyn [1 ]
Choi, Jua [1 ]
Vo, Ashley A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Kidney Transplant, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Transplant Immunol Lab, Los Angeles, CA 90048 USA
来源：
TRANSPLANTATION | 2020年 / 104卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
380.2
引用
收藏
页码：S67 / S68
页数：2
相关论文
共 50 条
  • [21] CLAZAKIZUMAB® (ANTI-IL-6) FOR DESENSITIZATION OF HIGHLY-HLA SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT (NCT03380962)
    Vo, Ashley
    Ammerman, Noriko
    Huang, Edmund
    Toyoda, Mieko
    Ge, Shili
    Peng, Alice
    Najjar, Reiad
    Williamson, Summer
    Myers, Catherine
    Sethi, Supreet
    Lim, Kathlyn
    Choi, Jua
    Jordan, Stanley
    TRANSPLANTATION, 2020, 104 (09) : S104 - S105
  • [22] Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
    Shin, B.
    Ge, S.
    Jimenez, A.
    Ammerman, N.
    Vo, A.
    Zhang, R.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 737 - 738
  • [23] Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation
    Lavacca, Antonio
    Presta, Roberto
    Gai, Chiara
    Mella, Alberto
    Gallo, Ester
    Camussi, Giovanni
    Abbasciano, Isabella
    Barreca, Antonella
    Caorsi, Cristiana
    Fop, Fabrizio
    Messina, Maria
    Rossetti, Maura
    Biancone, Luigi
    CLINICAL TRANSPLANTATION, 2020, 34 (08)
  • [24] Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
    Nickerson, Peter W.
    Boehmig, Georg A.
    Chadban, Steve
    Kumar, Deepali
    Mannon, Roslyn B.
    van Gelder, Teun
    Lee, James C.
    Adler, Scott
    Chong, Edward
    Djamali, Arjang
    TRIALS, 2022, 23 (01)
  • [25] Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
    Peter W. Nickerson
    Georg A. Böhmig
    Steve Chadban
    Deepali Kumar
    Roslyn B. Mannon
    Teun van Gelder
    James C. Lee
    Scott Adler
    Edward Chong
    Arjang Djamali
    Trials, 23
  • [26] Treatment of Chronic Active Antibody-Mediated Kidney Transplant Rejection With Intravenous Immunoglobulin
    Rapetskaya, Nadzeya
    Komissarov, Kirill
    Kalachyk, Aleh
    TRANSPLANTATION, 2022, 106 (09) : S572 - S572
  • [27] Tocilizumab for treatment of chronic active antibody-mediated rejection in kidney transplant recipients
    Boonpheng, Boonphiphop
    De Castro, Iris Camille C.
    Ng, Yue-Harn
    Blosser, Christopher
    Bakthavatsalam, Ramasamy
    Gimferrer, Idoia
    Smith, Kelly
    Leca, Nicolae
    CLINICAL TRANSPLANTATION, 2023, 37 (05)
  • [28] Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR).
    Shin, B.
    Ge, S.
    Petrosyan, A.
    Ammerman, N. F.
    Vo, A. A.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 452 - 452
  • [29] Rationale for the IMAGINE study for chronic active antibody-mediated rejection (caAMR) in kidney transplantation
    Nickerson, Peter W. W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 38 - 44
  • [30] CLAZAKIZUMAB (ANTI-IL-6) INDUCES FOXP3+TREGS IN HIGHLY HLA SENSITIZED PATIENTS RECEIVING HLAI KIDNEY TRANSPLANTATION (NCT03380962)
    Jordan, Stanley
    Ge, Shili
    Ammerman, Nori
    Toyoda, Mieko
    Huang, Edmund
    Peng, Alice
    Najjar, Reiad
    Sethi, Supreet
    Williamson, Summer
    Myers, Kate
    Lim, Kathlyn
    Choi, Jua
    Vo, Ashley A.
    TRANSPLANTATION, 2020, 104 (09) : S105 - S105
12345